Advertisement

Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients

  • Teodora Donisan
  • Dinu Valentin Balanescu
  • Gloria Iliescu
  • Konstantinos Marmagkiolis
  • Cezar IliescuEmail author
Reference work entry

Abstract

The management of acute coronary syndromes (ACS) in cancer patients may be complicated by cancer-related comorbidities, of which thrombocytopenia is common. Thrombocytopenic cancer patients are exposed to a simultaneous risk of both bleeding and thrombosis. Both antiplatelet regimens and invasive strategies for ACS have been shown to be safe in thrombocytopenic cancer patients. However, cancer patients are generally excluded from large, randomized cardiovascular trials. As a consequence, specific guidelines for the management of ACS in cancer patients, particularly in the setting of thrombocytopenia, are currently lacking. There are several important differences between the etiology and pathophysiology of ACS in cancer patients compared to the general population. These differences stem mainly from the prothrombotic state associated with malignancies and from the effect of anticancer therapies. Despite the proof of better survival in cancer patients with ACS treated with optimal medical therapy and invasive revascularization techniques, both are underused in this population. This chapter aims to present current data and available therapeutic strategies regarding ACS, thrombocytopenia, and antiplatelet therapy in critically ill cancer patients.

Keywords

Acute coronary syndrome Antiplatelet therapy Cancer Cardio-oncology Coronary angiography Thrombocytopenia Percutaneous coronary intervention 

References

  1. 1.
    Al-Hawwas M, Tsitlakidou D, Gupta N, Iliescu C, Cilingiroglu M, Marmagkiolis K. Acute coronary syndrome management in cancer patients. Curr Oncol Rep. 2018;20:78.CrossRefGoogle Scholar
  2. 2.
    Aleman BM, Van Den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, Van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21:3431–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:2354–94.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Anderson L, Quasim I, Soutar R, Steven M, Macfie A, Korte W. An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfus Med. 2006;16:31–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Ando G, Gragnano F, Calabro P, Valgimigli M. Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018;92:E518–26.CrossRefPubMedGoogle Scholar
  6. 6.
    Armanious MA, Mohammadi H, Khodor S, Oliver DE, Johnstone PA, Fradley MG. Cardiovascular effects of radiation therapy. Curr Probl Cancer. 2018;42:433–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Azzalini L, Tosin K, Chabot-Blanchet M, Avram R, Ly HQ, Gaudet B, Gallo R, Doucet S, Tanguay JF, Ibrahim R, Gregoire JC, Crepeau J, Bonan R, De Guise P, Nosair M, Dorval JF, Gosselin G, L’allier PL, Guertin MC, Asgar AW, Jolicoeur EM. The benefits conferred by radial access for cardiac catheterization are offset by a paradoxical increase in the rate of vascular access site complications with femoral access: the Campeau radial paradox. JACC Cardiovasc Interv. 2015;8:1854–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Bech GJ, De Bruyne B, Pijls NH, De Muinck ED, Hoorntje JC, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation. 2001;103:2928–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Bhatia N, Sawyer RD, Ikram S. Eptifibatide-induced profound thrombocytopenia after percutaneous intervention for acute coronary syndrome: a challenging clinical scenario. Methodist Debakey Cardiovasc J. 2017;13:248–52.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1116–39.CrossRefPubMedGoogle Scholar
  11. 11.
    Boero IJ, Paravati AJ, Triplett DP, Hwang L, Matsuno RK, Gillespie EF, Yashar CM, Moiseenko V, Einck JP, Mell LK, Parikh SA, Murphy JD. Modern radiation therapy and cardiac outcomes in breast cancer. Int J Radiat Oncol Biol Phys. 2016;94:700–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Boettcher BT, Olund TJ, Pagel PS. Acute severe thrombocytopenia occurring after administration of eptifibatide postpones emergent coronary artery surgery. Anesth Pain Med. 2016;6:e37575.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bogabathina H, Singireddy S, Shi R, Morris L, Abdulbaki A, Zabher H, Katikaneni P, Modi K. Does micropuncture technique really help reduce vascular complications? Cardiovasc Revasc Med. 2018;19:762–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Bolte J, Neumann U, Pfafferott C, Vogt A, Engel HJ, Mehmel HC, Von Olshausen KE. Incidence, management, and outcome of stent loss during intracoronary stenting. Am J Cardiol. 2001;88:565–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Bonadei I, Sciatti E, Vizzardi E, D’aloia A, Raddino R, Metra M. New frontiers in the management of acute coronary syndromes: cangrelor and elinogrel. Recent Pat Cardiovasc Drug Discov. 2014;9:22–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J. 2011;161:298–306.e1.CrossRefPubMedGoogle Scholar
  17. 17.
    Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:71–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Castaman G, Pieri L. Management of thrombocytopenia in cancer. Thromb Res. 2018;164(Suppl 1):S89–s93.CrossRefPubMedGoogle Scholar
  19. 19.
    Childers CP, Maggard-Gibbons M, Ulloa JG, Macqueen IT, Miake-Lye IM, Shanman R, Mak S, Beroes JM, Shekelle PG. Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement: a systematic review. Syst Rev. 2018;7:4.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Contursi A, Sacco A, Grande R, Dovizio M, Patrignani P. Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cell Mol Life Sci. 2017;74:3491–507.CrossRefPubMedGoogle Scholar
  21. 21.
    Cordero A, Lopez-Palop R, Carrillo P, Nunez J, Frutos A, Bertomeu-Gonzalez V, Yepez F, Alcantara N, Ribes F, Juskova M, Bertomeu-Martinez V. Prevalence and postdischarge incidence of malignancies in patients with acute coronary syndrome. Rev Esp Cardiol (Engl Ed). 2018;71:267–73.CrossRefGoogle Scholar
  22. 22.
    Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10:83–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet. 2013;381:496–505.CrossRefPubMedGoogle Scholar
  24. 24.
    Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O’hare T, HU S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–88.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Costa F, Van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet JL. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Cuisset T, Grosdidier C, Loundou AD, Quilici J, Loosveld M, Camoin L, Pankert M, Beguin S, Lambert M, Morange PE, Bonnet JL, Alessi MC. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv. 2013;6:854–63.CrossRefPubMedGoogle Scholar
  28. 28.
    Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage radiation-induced coronary artery disease. Heart. 2018;104:1647–53.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cutlip DE, Leon MB, Ho KK, Gordon PC, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Fitzpatrick MM, Desjardin A, Popma JJ, Kuntz RE, Baim DS. Acute and nine-month clinical outcomes after “suboptimal” coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol. 1999;34:698–706.CrossRefPubMedGoogle Scholar
  30. 30.
    Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:2021–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Damluji AA, Nelson DW, Valgimigli M, Windecker S, Byrne RA, Cohen F, Patel T, Brilakis ES, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, RAO SV, Moscucci M, Cohen MG. Transfemoral approach for coronary angiography and intervention: a collaboration of International Cardiovascular Societies. JACC Cardiovasc Interv. 2017;10:2269–79.CrossRefPubMedGoogle Scholar
  32. 32.
    Darby SC, Ewertz M, Mcgale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, Bhindi R, Lehman SJ, Walters D, Sapontis J, Janssens L, Vrints CJ, Khashaba A, Laine M, Van Belle E, Krackhardt F, Bojara W, Going O, Harle T, Indolfi C, Niccoli G, Ribichini F, Tanaka N, Yokoi H, Takashima H, Kikuta Y, Erglis A, Vinhas H, Canas Silva P, Baptista SB, Alghamdi A, Hellig F, Koo BK, Nam CW, Shin ES, Doh JH, Brugaletta S, Alegria-Barrero E, Meuwissen M, Piek JJ, Van Royen N, Sezer M, Di Mario C, Gerber RT, Malik IS, Sharp ASP, Talwar S, Tang K, Samady H, Altman J, Seto AH, Singh J, Jeremias A, Matsuo H, Kharbanda RK, Patel MR, Serruys P, Escaned J. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med. 2017;376:1824–34.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE. Scientific rationale for the inclusion and exclusion criteria for intravenous Alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581–641.CrossRefPubMedGoogle Scholar
  35. 35.
    Des Guetz G, Uzzan B, Chouahnia K, Morere JF. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol. 2011;6:197–202.CrossRefPubMedGoogle Scholar
  36. 36.
    Doi H, Maehara A, Mintz GS, Yu A, Wang H, Mandinov L, Popma JJ, Ellis SG, Grube E, Dawkins KD, Weissman NJ, Turco MA, Ormiston JA, Stone GW. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent trials. JACC Cardiovasc Interv. 2009;2:1269–75.CrossRefPubMedGoogle Scholar
  37. 37.
    Droppa M, Geisler T. What is the role of cangrelor in patients undergoing PCI? Curr Vasc Pharmacol. 2018;16:484–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Elmariah S, Doros G, Benavente OR, Bhatt DL, Connolly SJ, Yusuf S, Steinhubl SR, Liu Y, Hsieh WH, Yeh RW, Mauri L. Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease: a patient-level meta-analysis. Circ Cardiovasc Interv. 2018;11:e005795.CrossRefPubMedGoogle Scholar
  39. 39.
    Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma. 1996;20:435–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900–2.CrossRefPubMedGoogle Scholar
  41. 41.
    Faraday N. Pro: should aspirin be continued after cardiac surgery in the setting of thrombocytopenia? J Cardiothorac Vasc Anesth. 2006;20:112–3.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Farag M, Spinthakis N, Srinivasan M, Gorog DA. Should STEMI patients receive opiate analgesia? The morphine paradox. Curr Vasc Pharmacol. 2018;16:477–83.CrossRefPubMedGoogle Scholar
  43. 43.
    Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63:945–53.CrossRefPubMedGoogle Scholar
  44. 44.
    Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, Campana M, Vermes E, Marchand-Adam S. Coronary toxicities of Anti-PD-1 and Anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Target Oncol. 2018;13:509–515.Google Scholar
  45. 45.
    Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–41.CrossRefPubMedGoogle Scholar
  46. 46.
    Ganatra S, Sharma A, Levy MS. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc Interv. 2017;10:2334–7.CrossRefGoogle Scholar
  47. 47.
    Gensicke H, Al Sultan AS, Strbian D, Hametner C, Zinkstok SM, Moulin S, Bill O, Zini A, Padjen V, Kagi G, Pezzini A, Seiffge DJ, Traenka C, Raty S, Amiri H, Zonneveld TP, Lachenmeier R, Polymeris A, Roos YB, Gumbinger C, Jovanovic DR, Curtze S, Sibolt G, Vandelli L, Ringleb PA, Leys D, Cordonnier C, Michel P, Lyrer PA, Peters N, Tatlisumak T, Nederkoorn PJ, Engelter ST, Thrombolysis in Stroke Patients, C. Intravenous thrombolysis and platelet count. Neurology. 2018;90:e690–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Giannopoulos G, Deftereos S, Kolokathis F, Xanthopoulou I, Lekakis J, Alexopoulos D. P2Y12 receptor antagonists and morphine: a dangerous liaison? Circ Cardiovasc Interv. 2016;9:e004229.CrossRefPubMedGoogle Scholar
  49. 49.
    Giupponi L, Cantoni S, Morici N, Sacco A, Giannattasio C, Klugmann S, Savonitto S. Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: moving between systemic bleeding and stent thrombosis. Platelets. 2015;26:498–500.CrossRefPubMedGoogle Scholar
  50. 50.
    Giza DE, Boccalandro F, Lopez-Mattei J, Iliescu G, Karimzad K, Kim P, Iliescu C. Ischemic heart disease: special considerations in cardio-oncology. Curr Treat Options Cardiovasc Med. 2017;19:37.CrossRefPubMedGoogle Scholar
  51. 51.
    Giza DE, Iliescu G, Hassan S, Marmagkiolis K, Iliescu C. Cancer as a risk factor for cardiovascular disease. Curr Oncol Rep. 2017;19:39.CrossRefPubMedGoogle Scholar
  52. 52.
    Giza DE, Lopez-Mattei J, Vejpongsa P, Munoz E, Iliescu G, Kitkungvan D, Hassan SA, Kim P, Ewer MS, Iliescu C. Stress-induced cardiomyopathy in cancer patients. Am J Cardiol. 2017;120:2284–8.CrossRefGoogle Scholar
  53. 53.
    Gomez-Lara J, Radu M, Brugaletta S, Farooq V, Diletti R, Onuma Y, Windecker S, Thuesen L, Mcclean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv. 2011;4:992–1001.CrossRefPubMedGoogle Scholar
  54. 54.
    Gonda E, Edmundson A, Mann T. Late coronary stent infection: a unique complication after drug-eluting stent implantation. J Invasive Cardiol. 2007;19:E307–8.PubMedGoogle Scholar
  55. 55.
    Gong IY, Yan AT, Ko DT, Earle CC, Cheung WY, Peacock S, Hall M, Gale CP, Chan KKW. Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. Cancer. 2018;124:1269–78.CrossRefPubMedGoogle Scholar
  56. 56.
    Gore JM, Spencer FA, Gurfinkel EP, Lopez-Sendon J, Steg PG, Granger CB, Fitzgerald G, Agnelli G. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009;103:175–80.CrossRefPubMedGoogle Scholar
  57. 57.
    Gotberg M, Christiansen EH, Gudmundsdottir IJ, Sandhall L, Danielewicz M, Jakobsen L, Olsson SE, Ohagen P, Olsson H, Omerovic E, Calais F, Lindroos P, Maeng M, Todt T, Venetsanos D, James SK, KaregreN A, Nilsson M, Carlsson J, Hauer D, Jensen J, Karlsson AC, Panayi G, Erlinge D, Frobert O. Instantaneous wave-free ratio versus fractional flow reserve to guide PCI. N Engl J Med. 2017;376:1813–23.CrossRefGoogle Scholar
  58. 58.
    Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018;2:439–49.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Gross CM, Posch MG, Geier C, Olthoff H, Kramer J, Dechend R, Dietz R, Ozcelik C. Subacute coronary stent thrombosis in cancer patients. J Am Coll Cardiol. 2008;51:1232–3.CrossRefPubMedGoogle Scholar
  60. 60.
    Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol. 2016;142:471–9.CrossRefGoogle Scholar
  61. 61.
    Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188–99.CrossRefPubMedGoogle Scholar
  62. 62.
    Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949–55.CrossRefGoogle Scholar
  63. 63.
    Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013;310:1462–72.CrossRefPubMedGoogle Scholar
  64. 64.
    Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Grines CL, Marmagkiolis K. Vascular toxicities of cancer therapies: the old and the new–an evolving avenue. Circulation. 2016;133:1272–89.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Hillegass WB. End of the bare metal stent era? Catheter Cardiovasc Interv. 2016;88:49–50.CrossRefPubMedGoogle Scholar
  66. 66.
    Hvelplund A, Hansen PR. Subacute intracoronary stent thrombosis in a patient with polycythaemia vera. Ugeskr Laeger. 2006;168:4104–5.PubMedGoogle Scholar
  67. 67.
    Iannaccone M, D’ascenzo F, Vadala P, Wilton SB, Noussan P, Colombo F, Raposeiras Roubin S, Abu Assi E, Gonzalez-Juanatey JR, Simao Henriques JP, Saucedo J, Kikkert WJ, Nunez-Gil I, Ariza-Sole A, Song XT, Alexopoulos D, Liebetrau C, Kawaji T, Moretti C, Garbo R, Huczek Z, Nie SP, Fujii T, Correia LC, Kawashiri MA, Garcia Acuna JM, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Mollmann H, Shiomi H, Giordana F, Kowara M, Filipiak K, Wang X, Yan Y, Fan JY, Ikari Y, Nakahashi T, Sakata K, Gaita F, Yamagishi M, Kalpak O, Kedev S. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care. 2017.  https://doi.org/10.1177/2048872617706501.
  68. 68.
    Iannaccone MFDA, De Filippo O, Gagliardi M, Southern DA, Raposeiras-Roubin S, Abu-Assi E, Henriques JPS, Saucedo J, Gonzalez-Juanatey JR, Wilton SB, Kikkert WJ, Nunez-Gil I, Ariza-Sole A, Song X, Alexopoulos D, Liebetrau C, Kawaji T, Huczek Z, Nie SP, Fujii T, Correia L, Kawashiri MA, Garcia-Acuna JM, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Mollmann H, Shiomi H, Kowara M, Filipiak K, Wang X, Yan Y, Fan JY, Ikari Y, Nakahashi T, Sakata K, Yamagishi M, Moretti C, Gaita F, Kalpak O, Kedev S. Optimal medical therapy in patients with malignancy undergoing percutaneous coronary intervention for acute coronary syndrome: a BleeMACS sub-study. Am J Cardiovasc Drugs. 2017;17:61–71.CrossRefPubMedGoogle Scholar
  69. 69.
    Iannaccone M, Saint-Hilary G, Menardi D, Vadala P, Bernardi A, Bianco M, Montefusco A, Omede P, D’amico S, Piazza F, Scacciatella P, D’amico M, Moretti C, Biondi-Zoccai G, Gasparini M, Gaita F, D’ascenzo F. Network meta-analysis of studies comparing closure devices for femoral access after percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 2018;19:586–96.Google Scholar
  70. 70.
    Icli F, Karaoguz H, Dincol D, Demirkazik A, Gunel N, Karaoguz R, Uner A. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587–93.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Iezzi R, Pompili M, Posa A, Annicchiarico E, Garcovich M, Merlino B, Rodolfino E, Di Noia V, Basso M, Cassano A, Barone C, Gasbarrini A, Manfredi R, Colosimo C. Transradial versus transfemoral access for hepatic chemoembolization: intrapatient prospective single-center study. J Vasc Interv Radiol. 2017;28:1234–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Iliescu C, Balanescu DV, Donisan T, Giza DE, Munoz Gonzalez ED, Cilingiroglu M, Song J, Mukerji SS, Lopez-Mattei JC, Kim PY, Palaskas N, Mouhayar EN, Durand JB, Marmagkiolis K. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol. 2018;122:1465–70.CrossRefPubMedGoogle Scholar
  73. 73.
    Iliescu C, Durand JB, Kroll M. Cardiovascular interventions in thrombocytopenic cancer patients. Tex Heart Inst J. 2011;38:259–60.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Iliescu CA, Cilingiroglu M, Giza DE, Rosales O, Lebeau J, Guerrero-Mantilla I, Lopez-Mattei J, Song J, Silva G, Loyalka P, Paixao ARM, Yusuf SW, Perin E, Anderson VH, Marmagkiolis K. “Bringing on the light” in a complex clinical scenario: optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017;194:83–91.CrossRefPubMedGoogle Scholar
  75. 75.
    Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas KP, Leesar MA, Marmagkiolis K. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv. 2016;87:E202–23.CrossRefPubMedGoogle Scholar
  76. 76.
    Jao GT, Knovich MA, Savage RW, Sane DC. ST-elevation myocardial infarction and myelodysplastic syndrome with acute myeloid leukemia transformation. Tex Heart Inst J. 2014;41:234–7.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58:487–93.CrossRefGoogle Scholar
  78. 78.
    Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, Barba M, Yosuico VE, Schunemann H, Akl EA. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:Cd006650.PubMedGoogle Scholar
  79. 79.
    Khair T, Garcia B, Banerjee S, Brilakis ES. Contemporary approaches to perioperative management of coronary stents and to preoperative coronary revascularization: a survey of 374 interventional cardiologists. Cardiovasc Revasc Med. 2011;12:99–104.CrossRefPubMedGoogle Scholar
  80. 80.
    Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008;5:655–67.CrossRefPubMedGoogle Scholar
  81. 81.
    Kohl BA. Con: should aspirin be continued after cardiac surgery in the setting of thrombocytopenia? J Cardiothorac Vasc Anesth. 2006;20:114–6.CrossRefPubMedGoogle Scholar
  82. 82.
    Kolkailah AA, Alreshq RS, Muhammed AM, Zahran ME, Anas El-Wegoud M, Nabhan AF. Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease. Cochrane Database Syst Rev. 2018;4:Cd012318.PubMedGoogle Scholar
  83. 83.
    Kononczuk J, Surazynski A, Czyzewska U, Prokop I, Tomczyk M, Palka J, Miltyk W. alphaIIbbeta3-integrin ligands: abciximab and eptifibatide as proapoptotic factors in MCF-7 human breast cancer cells. Curr Drug Targets. 2015;16:1429–37.CrossRefPubMedGoogle Scholar
  84. 84.
    Landes U, Kornowski R, Bental T, Assali A, Vaknin-Assa H, Lev E, Iakobishvili Z. Long-term outcomes after percutaneous coronary interventions in cancer survivors. Coron Artery Dis. 2017;28:5–10.CrossRefPubMedGoogle Scholar
  85. 85.
    Leader A, Zelikson-Saporta R, Pereg D, Spectre G, Rozovski U, Raanani P, Hermoni D, Lishner M. The effect of combined aspirin and clopidogrel treatment on cancer incidence. Am J Med. 2017;130:826–32.CrossRefPubMedGoogle Scholar
  86. 86.
    Lee CW, Muo CH, Liang JA, Sung FC, Kao CH. Modest increase in risk of acute coronary syndrome associated with morphine use in cancer patients: a population-based nested case-control study. Eur J Oncol Nurs. 2014;18:295–8.CrossRefPubMedGoogle Scholar
  87. 87.
    Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, MEHRAN R, Mukherjee D, Newby LK, O’gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082–115.CrossRefPubMedGoogle Scholar
  88. 88.
    Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’gara PT, Sabatine MS, Smith PK, Smith SC Jr, Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis JS, Joglar JA, Pressler SJ, Wijeysundera DN. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016;152:1243–75.CrossRefPubMedGoogle Scholar
  89. 89.
    Li J, Elrashidi MY, Flammer AJ, Lennon RJ, Bell MR, Holmes DR, Bresnahan JF, Rihal CS, Lerman LO, Lerman A. Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J. 2013;34:1375–83.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Liebman HA. Thrombocytopenia in cancer patients. Thromb Res. 2014;133(Suppl 2):S63–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Lin YN, Chang YJ, Chen YH, Ko PY, Lin CL, Sung FC, Chang KC, Kao CH. Nationwide population-based cohort study on the association of acute coronary syndrome in patients with malignancies. Support Care Cancer. 2014;22:2707–13.CrossRefPubMedGoogle Scholar
  92. 92.
    Malik N, Banning AS, Belger M, Fakhouri W, Graham-Clarke PL, Banning A, Baumbach A, Blackman DJ, De Belder A, Lefevre T, Stables R, Zaman A, Gershlick AH. A risk scoring system to predict coronary stent thrombosis. Curr Med Res Opin. 2017;33:859–67.CrossRefPubMedGoogle Scholar
  93. 93.
    Mann DL, Krone RJ. Cardiac disease in cancer patients: an overview. Prog Cardiovasc Dis. 2010;53:80–7.CrossRefPubMedGoogle Scholar
  94. 94.
    Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D’agostino RB Sr, Braunwald E, Kereiakes DJ. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016;37:378–85.PubMedGoogle Scholar
  95. 95.
    Mccarthy CP, Bhambhani V, Pomerantsev E, Wasfy JH. In-hospital outcomes in invasively managed acute myocardial infarction patients who receive morphine. J Interv Cardiol. 2018;31:150–8.CrossRefPubMedGoogle Scholar
  96. 96.
    Mcclure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation. 1999;99:2892–900.CrossRefPubMedGoogle Scholar
  97. 97.
    Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17:729–36.PubMedGoogle Scholar
  98. 98.
    Mignatti A, Friedmann P, Slovut DP. Targeting the safe zone: a quality improvement project to reduce vascular access complications. Catheter Cardiovasc Interv. 2018;91:27–32.CrossRefPubMedGoogle Scholar
  99. 99.
    Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–13.CrossRefPubMedGoogle Scholar
  100. 100.
    Munoz E, Iliescu G, Vejpongsa P, Charitakis K, Karimzad K, Lopez-Mattei J, Yusuf SW, Marmagkiolis K, Iliescu C. Takotsubo stress cardiomyopathy: “Good News” in cancer patients? J Am Coll Cardiol. 2016;68:1143–4.CrossRefPubMedGoogle Scholar
  101. 101.
    Oikonomou EK, Repanas TI, Papanastasiou C, Kokkinidis DG, Miligkos M, Feher A, Gupta D, Kampaktsis PN. The effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: a systematic review and meta-analysis. Thromb Res. 2016;147:64–71.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Otsuka M, Shiode N, Nakao Y, Ikegami Y, Kobayashi Y, Takeuchi A, Harima A, Higaki T, Oi K, Dai K, Kawase T, Nakama Y, Suenari K, Nishioka K, Sakai K, Shimatani Y, Masaoka Y, Inoue I. Comparison of radial, brachial, and femoral accesses using hemostatic devices for percutaneous coronary intervention. Cardiovasc Interv Ther. 2018;33:62–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, Petrou M, Rapezzi C, Stone GW. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496–507.CrossRefPubMedGoogle Scholar
  104. 104.
    Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Smits PC, Kaiser C, D’ascenzo F, Frati G, Mancone M, Genereux P, Stone GW. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299–307.CrossRefPubMedGoogle Scholar
  105. 105.
    Papa ML, Capasso F, Pudore L, Torre S, Mango S, Russo V, Delrio P, Palaia R, Ruffolo F, D’eufemia MD, De Lucia D, Napolitano M, Di Micco P, Parisi V. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer. Exp Oncol. 2007;29:111–5.PubMedGoogle Scholar
  106. 106.
    Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol. 1998;16:2625–31.CrossRefPubMedGoogle Scholar
  107. 107.
    Patrono C, Rocca B. Aspirin, 110 years later. J Thromb Haemost. 2009;7(Suppl 1):258–61.CrossRefPubMedGoogle Scholar
  108. 108.
    Pijls NH, Van Schaardenburgh P, Manoharan G, Boersma E, Bech JW, Van’t Veer M, Bar F, Hoorntje J, Koolen J, Wijns W, De Bruyne B. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER study. J Am Coll Cardiol. 2007;49:2105–11.CrossRefPubMedGoogle Scholar
  109. 109.
    Piper WD, Malenka DJ, Ryan TJ Jr, Shubrooks SJ Jr, O’connor GT, Robb JF, Farrell KL, Corliss MS, Hearne MJ, Kellett MA Jr, Watkins MW, Bradley WA, Hettleman BD, Silver TM, Mcgrath PD, O’mears JR, Wennberg DE. Predicting vascular complications in percutaneous coronary interventions. Am Heart J. 2003;145:1022–9.CrossRefPubMedGoogle Scholar
  110. 110.
    Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53–8.CrossRefPubMedGoogle Scholar
  111. 111.
    Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408–17.CrossRefPubMedGoogle Scholar
  112. 112.
    Raphael CE, Spoon DB, Bell MR, Psaltis PJ, Kidd S, Loh SX, Lennon RJ, Singh M, Rihal C, Gulati R. Effect of preprocedural thrombocytopenia on prognosis after percutaneous coronary intervention. Mayo Clin Proc. 2016;91:1035–44.CrossRefPubMedGoogle Scholar
  113. 113.
    Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389:197–210.CrossRefPubMedGoogle Scholar
  114. 114.
    Reikvam H, Steien E, Hauge B, Liseth K, Hagen KG, Storkson R, Hervig T. Thrombelastography. Transfus Apher Sci. 2009;40:119–23.CrossRefPubMedGoogle Scholar
  115. 115.
    Resnick NJ, Kim E, Patel RS, Lookstein RA, Nowakowski FS, Fischman AM. Uterine artery embolization using a transradial approach: initial experience and technique. J Vasc Interv Radiol. 2014;25:443–7.CrossRefPubMedGoogle Scholar
  116. 116.
    Robertson L, Andras A, Colgan F, Jackson R. Vascular closure devices for femoral arterial puncture site haemostasis. Cochrane Database Syst Rev. 2016;3:Cd009541.PubMedGoogle Scholar
  117. 117.
    Rohrmann S, Witassek F, Erne P, Rickli H, Radovanovic D. Treatment of patients with myocardial infarction depends on history of cancer. Eur Heart J Acute Cardiovasc Care. 2017.  https://doi.org/10.1177/2048872617729636.
  118. 118.
    Sadeghian S, Darvish S, Davoodi G, Salarifar M, Mahmoodian M, Fallah N, Karimi AA. The association of opium with coronary artery disease. Eur J Cardiovasc Prev Rehabil. 2007;14:715–7.CrossRefPubMedGoogle Scholar
  119. 119.
    Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, Champion JC, Swafford J, Shaw AD, Lenihan DJ, Durand JB. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109:621–7.CrossRefPubMedGoogle Scholar
  120. 120.
    Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, Mccullough JJ, Mcintyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519–38.CrossRefPubMedGoogle Scholar
  121. 121.
    Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22:1404–12.CrossRefPubMedGoogle Scholar
  122. 122.
    Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van De Werf F, Wilcox R, Morrow DA. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial. Lancet. 2012;380:1317–24.CrossRefPubMedGoogle Scholar
  123. 123.
    Serebruany VL, Cherepanov V, Cabrera-Fuentes HA, Kim MH. Solid cancers after antiplatelet therapy: confirmations, controversies, and challenges. Thromb Haemost. 2015;114:1104–12.CrossRefPubMedGoogle Scholar
  124. 124.
    Sharma A, Ferguson C, Bainey KR. Thrombocytopenia in acute coronary syndromes: etiologies and proposed management. Can J Cardiol. 2015;31:809–11.CrossRefPubMedGoogle Scholar
  125. 125.
    Shin D, Mohanty BD, Lee ES. Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis. Coron Artery Dis. 2018;29:670–80.CrossRefPubMedGoogle Scholar
  126. 126.
    Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komocsi A, Dezsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, Koltowski L, Mehilli J, Huczek Z, Massberg S. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747–57.CrossRefPubMedGoogle Scholar
  127. 127.
    Stiermaier T, Moeller C, Oehler K, Desch S, Graf T, Eitel C, Vonthein R, Schuler G, Thiele H, Eitel I. Long-term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences. Eur J Heart Fail. 2016;18:650–6.CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    Sugiyama T, Xing L, Yamamoto E, Fracassi F, Lee H, Yu B, Jang IK. Thrombus resolution with tirofiban in the conservative management of patients presenting with plaque erosion. Coron Artery Dis. 2018;29:301–8.CrossRefPubMedGoogle Scholar
  129. 129.
    Sun B, Liu Z, Yin H, Wang T, Chen T, Yang S, Jiang Z. Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96:e8223.CrossRefGoogle Scholar
  130. 130.
    Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs. 2011;25:159–69.CrossRefPubMedGoogle Scholar
  131. 131.
    Tamhane UU, Gurm HS. The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin Drug Saf. 2008;7:809–19.CrossRefPubMedGoogle Scholar
  132. 132.
    Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–73.CrossRefPubMedGoogle Scholar
  133. 133.
    Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, Maccarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929–38.CrossRefGoogle Scholar
  134. 134.
    Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT. Comparison of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005;97:104–8.CrossRefPubMedGoogle Scholar
  135. 135.
    Tornvall P, Collste O, Ehrenborg E, Jarnbert-Petterson H. A case-control study of risk markers and mortality in Takotsubo stress cardiomyopathy. J Am Coll Cardiol. 2016;67:1931–6.CrossRefPubMedGoogle Scholar
  136. 136.
    Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, Maule MM, Merletti F, Gatta G. Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17:896–906.CrossRefPubMedGoogle Scholar
  137. 137.
    Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with Prasugrel) study. J Am Coll Cardiol. 2012;59:2159–64.CrossRefPubMedGoogle Scholar
  138. 138.
    Vaitkus PT, Dickens C, Mcgrath MK. Low bleeding risk from cardiac catheterization in patients with advanced liver disease. Catheter Cardiovasc Interv. 2005;65:510–2.CrossRefPubMedGoogle Scholar
  139. 139.
    Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60.CrossRefPubMedGoogle Scholar
  140. 140.
    Van Belle E, Rioufol G, Pouillot C, Cuisset T, Bougrini K, Teiger E, Champagne S, Belle L, Barreau D, Hanssen M, Besnard C, Dauphin R, Dallongeville J, El Hahi Y, Sideris G, Bretelle C, Lhoest N, Barnay P, Leborgne L, Dupouy P. Outcome impact of coronary revascularization strategy reclassification with fractional flow reserve at time of diagnostic angiography: insights from a large French multicenter fractional flow reserve registry. Circulation. 2014;129:173–85.CrossRefPubMedGoogle Scholar
  141. 141.
    Velders MA, Boden H, Hofma SH, Osanto S, Van Der Hoeven BL, Heestermans AA, Cannegieter SC, Jukema JW, Umans VA, Schalij MJ, Van Boven AJ. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol. 2013;112:1867–72.CrossRefGoogle Scholar
  142. 142.
    Wang J, Cai X, Cheng X, Song P, Jiang S, Gong J. Acute myocardial infarction caused by tumor-associated thrombotic thrombocytopenic purpura: case report. Med Princ Pract. 2014;23:289–91.CrossRefPubMedGoogle Scholar
  143. 143.
    Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004;110:278–84.CrossRefPubMedGoogle Scholar
  144. 144.
    Wang TY, Ou FS, Roe MT, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009;119:2454–62.CrossRefPubMedGoogle Scholar
  145. 145.
    Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, Hamilton AS, Oakley-Girvan I, Keel G, Aziz NM. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv. 2013;7:253–61.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Whitlock MC, Yeboah J, Burke GL, Chen H, Klepin HD, Hundley WG. Cancer and its association with the development of coronary artery calcification: an assessment from the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2015;4:e002533.CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    Winther JF, Bhatia S, Cederkvist L, Gudmundsdottir T, Madanat-Harjuoja L, Tryggvadottir L, Wesenberg F, Hasle H, Sallfors Holmqvist A. Risk of cardiovascular disease among Nordic childhood cancer survivors with diabetes mellitus: a report from adult life after childhood cancer in Scandinavia. Cancer. 2018;124:4393–400.CrossRefPubMedGoogle Scholar
  148. 148.
    Wiviott SD, Braunwald E, Mccabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.CrossRefPubMedGoogle Scholar
  149. 149.
    Xiang E, Ahuja T, Raco V, Cirrone F, Green D, Papadopoulos J. Anticoagulation prescribing patterns in patients with cancer. J Thromb Thrombolysis. 2018;45:89–98.CrossRefPubMedGoogle Scholar
  150. 150.
    Xu J, Murphy SL, Kochanek KD, Bastian B, Arias E. Deaths: final data for 2016. Natl Vital Stat Rep. 2018;67:1–76.PubMedGoogle Scholar
  151. 151.
    Yamada R, Bracewell S, Bassaco B, Camacho J, Anderson MB, Conrad A, Lynn C, Burns P, Collins H, Guimaraes M. Transradial versus transfemoral arterial access in liver Cancer embolization: randomized trial to assess patient satisfaction. J Vasc Interv Radiol. 2018;29:38–43.CrossRefPubMedGoogle Scholar
  152. 152.
    Yang EH, Perez E, Zhiroff KA, Burstein S. Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia. Tex Heart Inst J. 2011;38:174–8.PubMedPubMedCentralGoogle Scholar
  153. 153.
    Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.CrossRefGoogle Scholar
  154. 154.
    Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735–49.CrossRefPubMedPubMedCentralGoogle Scholar
  155. 155.
    Yetis Sayin B, Oto MA. Acute coronary syndrome in cancer patients. Am J Cardiovasc Drugs. 2018;18:361–72.CrossRefPubMedGoogle Scholar
  156. 156.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.CrossRefPubMedGoogle Scholar
  157. 157.
    Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35:443–50.CrossRefPubMedPubMedCentralGoogle Scholar
  158. 158.
    Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex Heart Inst J. 2010;37:336–40.PubMedPubMedCentralGoogle Scholar
  159. 159.
    Zhao SW, Wang YP, Xu LD, Gang W. The application of thromboelastogram in detection of indexes of antiplatelet therapy for coronary heart disease. J Thorac Dis. 2016;8:3515–20.CrossRefPubMedPubMedCentralGoogle Scholar
  160. 160.
    Zhou X, Wu X, Sun H, Li J. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: a systematic review and meta-analysis. J Evid Based Med. 2017;10:136–44.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Teodora Donisan
    • 1
  • Dinu Valentin Balanescu
    • 1
  • Gloria Iliescu
    • 2
  • Konstantinos Marmagkiolis
    • 3
  • Cezar Iliescu
    • 1
    Email author
  1. 1.Department of CardiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of General Internal MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Florida Hospital Pepin Heart InstituteTampaUSA

Personalised recommendations